title: Thioaptamers targeting dengue virus type-2 envelope protein domain III.
abstract: Thioaptamers targeting the dengue-2 virus (DENV-2) envelope protein domain III (EDIII) were developed. EDIII, which contains epitopes for binding neutralizing antibodies, is the putative host-receptor binding domain and is thus an attractive target for development of vaccines, anti-viral therapeutic and diagnostic agents. Thioaptamer DENTA-1 bound to DENV-2 EDIII adjacent to a known neutralizing antibody binding site with a dissociation constant of 154nM.
authors.affiliation: Center for Proteomics and Systems Biology of The Brown Foundation Institute of Molecular Medicine for the Prevention of Human Diseases, The University of Texas Health Science Center at Houston, Houston, TX 77030, USA.
authors.forename: Sai Hari A
authors.initials: SH
authors.lastname: Gandham
authors.affiliation: Center for Proteomics and Systems Biology of The Brown Foundation Institute of Molecular Medicine for the Prevention of Human Diseases, The University of Texas Health Science Center at Houston, Houston, TX 77030, USA; Department of Nanomedicine and Biomedical Engineering, The University of Texas Health Science Center at Houston, Houston, TX 77030, USA.
authors.forename: David E
authors.initials: DE
authors.lastname: Volk
authors.affiliation: Center for Proteomics and Systems Biology of The Brown Foundation Institute of Molecular Medicine for the Prevention of Human Diseases, The University of Texas Health Science Center at Houston, Houston, TX 77030, USA; Department of Nanomedicine and Biomedical Engineering, The University of Texas Health Science Center at Houston, Houston, TX 77030, USA.
authors.forename: Ganesh L R
authors.initials: GL
authors.lastname: Lokesh
authors.affiliation: Center for Proteomics and Systems Biology of The Brown Foundation Institute of Molecular Medicine for the Prevention of Human Diseases, The University of Texas Health Science Center at Houston, Houston, TX 77030, USA.
authors.forename: Muniasamy
authors.initials: M
authors.lastname: Neerathilingam
authors.affiliation: Center for Proteomics and Systems Biology of The Brown Foundation Institute of Molecular Medicine for the Prevention of Human Diseases, The University of Texas Health Science Center at Houston, Houston, TX 77030, USA; Department of Nanomedicine and Biomedical Engineering, The University of Texas Health Science Center at Houston, Houston, TX 77030, USA. Electronic address: David.G.Gorenstein@uth.tmc.edu.
authors.forename: David G
authors.initials: DG
authors.lastname: Gorenstein
mesh_terms: D057134:Antibodies, Neutralizing / Q000276:immunology; D000998:Antiviral Agents / Q000494:pharmacology*; D052157:Aptamers, Nucleotide / Q000737:chemistry / Q000494:pharmacology*; D001483:Base Sequence; D003716:Dengue Virus / Q000737:chemistry / Q000187:drug effects*; D009682:Magnetic Resonance Spectroscopy; D014759:Viral Envelope Proteins / Q000737:chemistry / Q000187:drug effects* / Q000276:immunology
chemical_list: D057134:Antibodies, Neutralizing; D000998:Antiviral Agents; D052157:Aptamers, Nucleotide; D014759:Viral Envelope Proteins
keywords: Anti-viral; Dengue virus; Diagnostic agent; Envelope protein; SELEX; Thioaptamer